Wednesday, November 6th: 8:00 a.m. – 5:00 p.m. CT
Thursday, November 7th: 8:00 a.m. – 2:00 p.m. CT
Erik R. Dubberke, MD, MSPH
Wednesday Conference Chair & Keynote Speaker
Dr. Dubberke, MD, MSPH is an Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University. He attended medical school at the University of Illinois at Chicago and did his medicine and infectious diseases training at Barnes-Jewish Hospital/Washington University. He received a Master’s of Science in Public Health from St. Louis University. His main research interests are in the epidemiology, diagnosis, treatment, and prevention of Clostridium difficile infection (CDI). Dr. Dubberke has over 115 publications, and made the Thomson Reuters list of Highly Cited Researchers in 2015 and 2016. He was the lead author for the CDI component of the Society for Healthcare Epidemiology of America (SHEA) Compendium to Prevent Healthcare-Associated Infections and is on the panel updating the SHEA/IDSA CDI clinical guidelines. He has also represented SHEA as a Key Informant for the AHRQ Evidence-based Practice Center C. difficile review and at the Department of Health and Human Services Road Map to Eliminate HAI 2013 Action Plan Conference.
Presentation Topic: “Community-Onset Clostridium difficile Infection.”
Paul Feuerstadt, MD, FACG
Dr. Feuerstadt, MD, FACG, is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Presentation Topic: “An Overview of C. difficile infection: Pathophysiology and Epidemiology.”
Doe Kley, RN, CIC, MPH
Doe Kley, Senior Infection Preventionist for The Clorox Company joined as a member of the Clinical & Scientific Affairs Team in 2018. Doe is a registered nurse and is board certified in infection control & epidemiology. She holds a bachelor’s degree in microbiology and completed a master’s degree in public health at the University of Nevada. Doe has nearly 20 years of acute care infection prevention experience working in large healthcare systems such as Intermountain Healthcare in Utah and Kaiser Permanente in California. In her current role, she provides consultative services using her clinical expertise, input, and review of key materials to not only support marketing and sales, but also the development of practice tools for clinicians. Doe also engages with and provides thought leadership to external industry partners.
Presentation Topic: “Implications of Regulatory Changes for Infection Control in Long Term Care”
Maureen Spencer, RN, M.Ed.
Maureen Spencer, RN, M.Ed. has been board certified in infection control (CIC) for over 30 years and is currently the Director, Clinical Implementation at Accelerate Diagnostics, providing educational and consultative services to the sales and marketing teams in the US. She was previously the Corporate Director, Infection Prevention for Universal Health Services in King of Prussia, PA, Infection Control Manager at New England Baptist Hospital, Director Infection Control Unit at Mass General Hospital and other Boston hospitals in a career that has spanned over 40 years.
Presentation Topic: “Rapid Diagnostics for Sepsis and Antimicrobial Resistance.”
Glenn S. Tillotson, Ph.D., FRSM, FCCP
Dr. Tillotson, Ph.D., FRSM, FCCP has 30+ years of pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management, and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin and other antibacterials. Glenn has held several key committee positions at the American College of Chest Physicians; he is on the Scientific Steering Committee for the GTCBio. Annual Summit on Anti-infective Partnering. Currently, Dr. Tillotson has published >140 peer-reviewed manuscripts, presented >270 scientific posters and is on several journals Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine and F1000.
Presentation Topic: “Antibiotics- the Bacterial Response and the Human Efforts to Avoid the Resistance Crisis.“
Clifford L. McDonald, MD
Dr. McDonald, MD graduated from Northwestern University Medical School. He completed a medical microbiology fellowship at Duke University and is a former member of CDC’s Epidemic Intelligence Service. Dr. McDonald is currently the Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC. He has first-authored or co-authored over 100 peer-reviewed publications on subjects related to healthcare and infectious disease epidemiology.
Presentation Topic: “Clostridioides difficile 2019 Updates From the Centers for Disease Control and Prevention (CDC) .”
Norman B. Javitt, MD, Ph.D.
Dr. Javitt, MD, Ph.D., is a research doctor in New York, New York. He received his medical degree from Duke University School of Medicine and has been in practice for more than 20 years. Education and Medical Training: Mount Sinai School of Medicine, Residency, Internal Medicine Mount Sinai School of Medicine Residency, Internal Medicine, Mount Sinai School of Medicine, Internship, Transitional Year Duke University School of Medicine Medical School. Elected Member The American Society for Clinical Investigation, 1969.
Presentation Topic: “Ursodeoxycholic Acid for the Management of Recurrent C. difficile Infection.”
Mary Beth Dorr, Ph.D.
Dr. Dorr, Ph.D. is the product development lead for ZINPLAVA (bezlotoxumab), a monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Mary Beth has a pharmacy degree from the University of the Sciences’ Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran’s Administration Hospital in Philadelphia. She received a Ph.D. in pharmaceutics with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina Chapel Hill. Mary Beth joined the pharmaceutical industry in 1988, and has held a variety of positions related to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-infective products. Mary Beth has wide-ranging drug-development experience at several pharmaceutical companies, including Parke-Davis/Warner Lambert, Rhone-Poulenc Rorer/Aventis, Vicuron, and Wyeth/Pfizer, where she worked in pharmacokinetics/drug metabolism, clinical research, project and alliance management, and medical affairs. Mary Beth joined Merck in 2011 to direct the C. difficile monoclonal antibody clinical development program and led the clinical team through product registration and launch. In addition to her role as the product development team lead, she is responsible for the bezlotoxumab publication strategy and is the clinical director for the pediatric development program for bezlotoxumab.
Presentation Topic: “C. diff. Infections In Patients With Cancer: Subgroup Analyses from the MODIFY Trials.”
Ms. Jones is the Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Courtney has been part of the Rebiotix team since 2012, where she applied her background in systems ecology to product development, corporate project management and social media outreach for the microbiota-based technologies currently under development at Rebiotix. Ms. Jones received her undergraduate degree from Macalester College and project management training from the University of St. Thomas in St. Paul, Minnesota.
Presentation Topic: “What Shapes the Microbiome? Research and 2-Year Study of a Microbiota-based Therapy for Recurrent CDI”
Russ Stephens is the Vice President of Business for Development for Synexis. Following studies at the University of Georgia and Fribourg University in Geneva, Switzerland, he launched a career in Medical Device and Technology Development. During his 15 years career, Russ has launched several technologies ranging from devices for the treatment of peripheral vascular disease and tumor ablation to stroke and aneurysm treatment. Russ serves on several Boards supporting technology incubators in the med device space. Additionally, he is active with numerous legislative efforts supporting physicians and clinicians in their effort to build a progressive healthcare environment.
Presentation Topic: “Enhancing Environmental Bundles with Dry Hydrogen Peroxide.”
Bill Rutala, Ph.D., MPH, CIC
Dr. Rutela is the Director and co-founder of the Statewide Program for Infection Control and Epidemiology and a Research Professor for the Division of Infectious Diseases at the University of North Carolina’s School of Medicine. He was the Director of Hospital Epidemiology, Occupational Health and Safety Program at the University of North Carolina Hospitals for 38 years before retiring in May 2017. He is a retired Colonel with the U.S. Army Reserve and is certified in infection control. He has been an advisor to the Centers for Disease Control and Prevention (a former member of the Healthcare Infection Control Practices Advisory Committee [HICPAC], 1999-2003), the Food and Drug Administration (a former member of the General Hospital and Personal Use Devices Panel), the U.S. Environmental Protection Agency (a member of the Scientific Advisory Panel on Antimicrobial Research Strategies for Disinfectants) and the Federal Trade Commission. Dr. Rutala is a member of various committees on the local, state, national and international levels as well as several professional societies including the American Society for Microbiology, Association for Professionals in Infection Control and Epidemiology and the Society of Healthcare Epidemiology of America. He serves on the editorial board of the Infection Control and Hospital Epidemiology and The Journal of Hospital Infection. ~ Sponsored by PDI ~
Presentation Topic: ” Preventable Patient Harm: A Bundled Approach to
Reducing C. difficile Infection.”
Robert J. Boston photograph
Jennie Kwon, DO, MSCI
Dr. Kwon, DO, MSCI is an Assistant Professor of Medicine in the Infectious Diseases Division at Washington University School of Medicine in St. Louis, and an Associate Hospital Epidemiologist at Barnes-Jewish Hospital. The Kwon Lab focuses on the epidemiology, transmission, and prevention of infections due to antibiotic-resistant organisms (ARO) and Clostridium difficile. Dr. Kwon conducts clinical and translational research assessing the fecal microbiome in patients with ARO infections, and the role of the microbiome of the built environment in ARO and C. difficile transmission. She conducts her research both in the laboratory and the patient bedside. Dr. Kwon’s work is funded by the CDC, NIH, and multiple foundations. Dr. Kwon was the 2016-2018 National Academy of Medicine (NAM) Anniversary Fellow, is currently the Chair of the Society for Healthcare Epidemiology of America (SHEA) Awards Committee, and a member of the SHEA Research Committee. She is also a member of the Infectious Diseases Society of America Research Committee. Dr. Kwon’s experiences as a clinician, scientist, and NAM Fellow encompass her interests to translate the latest research findings into better quality care and outcomes for patients.
Presentation Topic:: “Diagnostic Stewardship for Clostridioides difficile Testing.”
Nicola Petrosillo, MD, FESCMID
Dr. Petrosillo, MD, FESCMID earned a degree of Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became a specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became a hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy. He is a fellow of the Pulmonary Vascular Research Institute and leader of the international task-force for pulmonary hypertension associated with HIV, since 2007. He is a member of the Professional Affairs SubCommittee on Infectious Diseases and a member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is Professor of Infectious Diseases at the Medical School of Specialization in Hygiene of the Tor Vergata University, Rome, and presently Director, Clinical & Research Department for Infectious Diseases National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS.
Presentation Topic: “Is Surveillance of Clostridioides difficile (C.diff.) Infection a Tool for Prevention?”
C. diff. Survivor
Mrs. Dayle Skelly
C. diff. Survivors join us to share personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes and losses endured from this life-threatening infection and how each recurrent C. difficile infection (rCDI) impacted their lives.
Presentation Topic: “C. diff. Survivor’s Journey. “
Simon M. Cutting, Ph.D.
Professor Cutting of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus Clostridium difficile.. His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors.
Presentation Topic: “Risk factors Linked to a C. difficile Infection.”
Joan Hebden, MS, RN, CIC, FAPIC
Ms. Hebden received her baccalaureate and master’s degrees from the University of Maryland School of Nursing. She is currently the President of IPC Consulting Group LLC, a Maryland-based company providing infection prevention consultation and research coordination in acute and non-acute care settings. She served as the Director of Infection Prevention and Control for 28 years at the University of Maryland Medical Center in Baltimore, Maryland. An accomplished practitioner, Ms. Hebden is an invited speaker at national epidemiology conferences, participates in research regarding the transmission of multi-drug resistant bacteria, and has multiple publications in medical and infection control journals. She is certified in infection control through the Certification Board of Infection Control and Epidemiology, is an active member of the Society for Healthcare Epidemiologists of America (SHEA) and the Association for Professionals in Infection Control (APIC), serves as a section editor and reviewer for the American Journal of Infection Control and is a fellow of APIC. She was the recipient of the 2018 SHEA Advanced Practice IP award.
Presentation Topic: “Unveiling the Shroud of C. diff. Infection Reporting to CDC’s National Healthcare Safety Network: The Good, the Bad and the Ugly.”
Priya Balachandran, Ph.D.
Dr. Balachandran is a Vice President at Applied Silver, Inc., a company that is transforming everyday linens and clothing used in healthcare, sports, hotels, and homes into germ killers, infection fighters and health protectors. Here she leads clinical applications and marketing initiatives. Dr. Balachandran has deep experience in developing and commercializing genomics and diagnostic products for microbial surveillance in healthcare, food safety, and pharmaceutical manufacturing. She also has a research background with multiple patents and peer-reviewed publications to her name. She is an active member of the Association of Professionals in Infection Control and Epidemiology, American Society for Microbiology and Infectious Disease Society of America. Prior to Applied Silver, Dr. Balachandran held leadership positions in product marketing at NuGEN Technologies, global product management at Thermo Fisher Scientific, and scientific and business roles at Life Technologies. Dr. Balachandran received her Ph.D. from the University of Alabama at Birmingham and completed her postdoctoral fellowship at the University of California at San Francisco.
Presentation Topic: “Addressing Contaminated Soft Surfaces and Infection Risk Through
Antimicrobial Textile Intervention.”
Michelle Avery, PhD
Michelle Avery is the Senior Director of Patient Engagement for Summit Therapeutics. She previously worked at MacDougall Biomedical Communications, where she provided investor, media and corporate communications for life science companies. Michelle received her PhD in neuroscience from the University of Massachusetts Medical School.
Presentation Topic: “Ridinilazole: A Targeted Antibiotic for CDI in Phase 3 Clinical Trials”
Dale Gerding, MD, FACP, FIDSA
Thursday Conference Chair & Keynote Speaker
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position, Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA) and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.
Presentation Topic: “Clostridioides difficile Infection Diagnosis: From Guidelines to New Toxin Tests”
Doran L. Fink, MD, Ph.D.
Dr. Fink, MD, Ph.D., is the Deputy Director (Clinical) in the Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration (FDA). Dr. Fink joined FDA as a Medical Officer in 2010 and has been responsible for primary and supervisory review of a broad portfolio of vaccines and related biological products. He currently oversees all clinical and toxicological review activities in the Division, which is responsible for the regulation of investigational vaccines and live biotherapeutic products (including fecal microbiota for transplantation) in clinical development for the prevention or treatment of C. difficile disease. Dr. Fink is board certified in Pediatrics and Pediatric Infectious Diseases. He received his MD and PhD (Molecular Microbiology and Microbial Pathogenesis) degrees in 2003 through the Medical Scientist Training Program at Washington University in St. Louis School of Medicine and subsequently completed his residency and fellowship training in 2006 (Pediatrics) and 2010 (Pediatric Infectious Diseases) at The Johns Hopkins University School of Medicine.
Presentation Topic: “Clinical Trials To Support Development and Licensure of Products for Treatment and Prevention of C. difficile Disease – FDA/CBER Regulatory Perspective.”
Larry Kociolek, MD, MSCI
Dr. Kociolek, MD, MSCI, is the Associate Medical Director of Infection Prevention and Control at Ann & Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine (NUFSM). Dr. Kociolek received his medical degree from St. Louis University School of Medicine, completed a pediatrics residency and chief residency at the University of Chicago, and completed pediatric infectious diseases fellowship at Lurie Children’s/NUFSM where he now serves on faculty. Dr. Kociolek’s NIH-funded translational research program is focused on several aspects of C. difficile infections in children, including the emergence of new C. difficile strain types, the transmission of C. difficile, improving the reliability and utilization of diagnostics tests, and better understanding the role of immunity in preventing C. difficile in children. At Lurie Children’s, Dr. Kociolek has led quality-improvement initiatives to optimize C. difficile testing and treatment. He has worked with the CDC to identify priority areas of C. difficile investigation in children and serves on the Society for Healthcare Epidemiology of America Pediatric Leadership Council Steering Committee, whose primary goal is to shape the national agenda for research, education, and advocacy for reducing healthcare-associated infections in children.
Presentation Topic: “Not Just Small Adults: Unique Aspects of C. difficile Infection in Children.”
Christopher Polage, MD, MAS
Dr. Polage, MD, MAS received a bachelor’s degree in Biology (1992) and Doctor of Medicine (2000) from the University of New Mexico where he was a post sophomore fellow in pathology and participated in infectious disease research involving Hantavirus. He completed a clinical internship in Internal Medicine at the University of Colorado and residency training in anatomic and clinical pathology at the University of Utah, receiving an award for research involving the identification of non-fermenting Gram negative bacteria via amplification and sequencing of 16s rDNA. He stayed in Utah to complete a two-year fellowship in Medical Microbiology at ARUP Laboratories, serving as the Acting Assistant Medical Director of Mycobacteriology during his second year. Throughout his medical school, residency and fellowship training, Christopher Polage was actively involved in medical relief and research-related work in the developing world including Peru and Africa and was partially supported as a Yale/Johnson & Johnson Physician Scholar in International Health in 2005. Dr. Polage is presently the Medical Director, DUHS Clinical Microbiology Laboratory, The Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University School of Medicine.
Presentation Topic: “Toxin Testing, Treatment, and Outcomes: A Reanalysis of the
UC Davis Hospital Diarrhea Study and Preliminary Results of the UC and Friends Project.”
Sahil Khanna, MD, M.B.B.S
Dr. Khanna, MD, MBBS, is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at the University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. Dr. Khanna has completed a Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations. He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic: “Fecal Transplant for C. difficile: Clinical Experience and Trials!”
Martha Clokie, Ph.D., MSc, BSc
Dr. Clokie, Ph.D., MSc, BSc – Her research focuses on identifying, characterizing and developing bacteriophages (viruses) that target and kill bacterial pathogens of medical relevance with the view to identifying novel antimicrobials. Clearly, this work has been impacted by our increasing concerns regarding antibiotic resistance because bacteriophages as natural enemies of bacteria can either be exploited as natural viruses, or they may encode novel products with antimicrobial properties. Her work is rooted in an ecological framework which I use both for virus discovery and the manipulation of microbiota associated with the disease. The major focus has been on Clostridium difficile where Dr. Clokie has isolated and characterized a large bacteriophage collection, and where she has developed in vitro, ex situand in vivo models to assess the mechanistic interactions of phages with their bacterial hosts and to assess their therapeutic potential. Dr. Clokie is now developing these phages as therapeutics. Dr. Clokie obtained a BSc in Biology from Dundee University in 1996 an MSc in Biodiversity from Edinburgh University in 1997, and a Ph.D. from Leicester in Molecular Ecology in 2001 and went on and did 6 years of Post-Doctoral research at the University of Warwick and in Scripps, La Jolla, San Diego. In 2007 Dr. Clokie was appointed as a lecturer at Leicester, in 2011 a Reader and in 2016 was promoted to Professor of Microbiology.
Presentation Topic: “The Development of Clostridioides difficile Bacteriophages for Therapeutic Purposes.”
A. Krishna Rao, MD, MS
Dr. Rao’s clinical, administrative, and research interests include the diagnosis and management of healthcare-associated infections, especially Clostridium difficile infection. His clinical work includes managing the University of Michigan Fecal Microbiota Transplantation (stool transplant) program for recurrent Clostridium difficile infection, a program that he co-founded. His primary research goal is to investigate how biochemical, microbiological, and clinical factors can help clinical decision-making in healthcare-associated infections, and he hopes to ultimately integrate these factors into robust risk-prediction algorithms for use by clinicians. He is currently funded by the NIH and/or CDC to study C. difficile infection, the effect of antibiotics on the gut microbiota, and infections from Gram-negative bacteria, including multi-drug resistant organisms, such as Klebsiella pneumoniae.
Presentation Topic: “Advances in Predictive Modeling for C. difficile Infection: Leveraging Big Data, Biomarkers, and the Gut Microbiota”
Jessica A. Bryant, PhD
Dr Bryant is a Scientist in the Microbiome Research and Development Group at Seres Therapeutics. She has contributed to Seres Therapeutics’ SER-262 program which aims to prevent C diff recurrences by rapidly resetting the microbiome to a healthy state following antibiotics, to preclude C diff from exploiting an antibiotic-induced dysbiotic gut. Dr. Bryant is also a member of Seres Therapeutics’ SER-155 team; developing a rationally-designed microbiome therapeutic candidate to prevent antibiotic-resistant bacterial infections. She received a bachelor’s degree in biology from the University of California Santa Cruz and a PhD from the Massachusetts Institute of Technology where she studied the complex interplay by which microbiomes and their environments both shape and are shaped by one other. During this time, she was a US Environmental Protection Agency Star Fellow. Her expertise lies in leveraging ecological principles and -omics tools to disentangling complexity in the human microbiome.
Presentation Topic: “Design & Evaluation of SER-262: A Fermentation-Derived Microbiome Therapeutic for the Prevention of Recurrence in Patients with Primary
Clostridioides difficile Infection.”
Stuart B. Johnson, MD,FIDSA, DTM&H
Dr. Johnson, MD,FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic: “Practical Aspects of C. difficile Infection Treatment In 2019.”
Pamela Suzanne Sears, Ph.D.,
Pamela Sears is the product development lead for DIFICID (fidaxomicin), an antibiotic approved for the treatment of C. difficile associated diarrhea in adults. Pam received her Ph.D. from the Scripps Research Institute, and after several years of conducting academic research, she has been working in the pharmaceutical industry since 2002 in early and late-stage development of antibacterial agents. She has previously worked at Optimer Pharmaceuticals and Cubist Pharmaceuticals, where she focused at various times on discovery, preclinical, and finally clinical development, and joined Merck in 2015. She currently leads the fidaxomicin and tedizolid phosphate programs at Merck.
Presentation Topic: “Safety and Efficacy of fidaxomicin vs. vancomycin in children with
C. difficile Infection: Results from a Phase 3 Study (SUNSHINE).”
Annaliesa Anderson , Ph.D., FAAM
Dr. Anderson, Ph.D., FAAM, has over 20 years of pharmaceutical research experience and is currently the Chief Scientific Officer for both the Bacterial Vaccines, within the Vaccine Research and Development Unit and The Hospitals Business Unit at Pfizer Inc. Her responsibilities include infectious disease vaccine research and development of the development and implementation of Pfizers anti-infective portfolio strategy. Dr. Anderson’s experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Neisseria meningitidis, Staphylococcus aureus, Clostridium difficile and Group B Streptococcus. In these roles, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept, and vaccine licensure. She was appointed to the role of VP and Chief Scientific Officer for Bacterial Vaccines in 2015 and obtained the CSO role for the Hospital Business Unit in 2019.
Presentation Topic: “Progress towards the development of a C. difficile prophylactic vaccine.”
Scientific Posters and Poster Presentations Will Also Be Included In the Conference Program Agenda.
Deinove; Yannick Pletan, MD, MSc, acting Chief Medical Officer.
TechLab; David Lylerly, Ph.D., Chief Scientific Officer.
PROGENABIOME; Sabine Hazan, MD, CEO.
Seres Therapeutics; Jessie Bryant, Ph. D.
Acurx Pharmaceuticals; Michael H Silverman, MD, FACP, Medical Director.
Rebiotix; Adam Harvey, PhD, Senior Clinical Research Scientist.
Trinity Guardion; Edmond A. Hooker, MD, DrPH, Clinical Advisor.
Vedanta Biosciences; Dmitri Bobilev, MD, VP, Head of Clinical Development.
Please contact Angelo Ortiz for more information firstname.lastname@example.org